Investment Rating - The report maintains a "BUY" rating for Goertek with a new target price (TP) of RMB 25.9, reflecting a 27% upside from the current price of RMB 20.39 [4][12]. Core Insights - Goertek's 1H24 revenue and net profit growth were reported at -11% and +190% year-on-year (YoY), respectively, aligning with earlier profit alerts [2]. - The gross profit margin (GPM) improved to 13.6% in 2Q24, up 4.4 percentage points quarter-on-quarter (QoQ) and 5.9 percentage points YoY, driven by enhanced efficiency and profitability in acoustics and smart products [2][7]. - The outlook for 2H24 and FY25E is positive, with expectations of continued GPM recovery and increased demand for augmented reality (AR) and virtual reality (VR) products, particularly with new launches from major players [2][12]. - Earnings per share (EPS) estimates for FY24-26E have been raised by 19-38% to reflect the strong performance in 1H24 and improved operating leverage [2][8]. Financial Performance Summary - 1H24 revenue was RMB 98,561 million, with a net profit of RMB 1,088.1 million, showing a significant recovery from previous quarters [3][11]. - The company expects net profit growth of +164% and +23% YoY for FY24 and FY25E, respectively [2][12]. - The report highlights strong revenue growth in precision components and acoustic products segments, with increases of +21% and +38% YoY, although smart products saw a decline of -32% YoY due to product cycle delays [2][10]. Earnings Revisions - Revenue estimates for FY24E have been adjusted to RMB 98,561 million, with net profit revised to RMB 2,876 million, reflecting a 19% increase from previous estimates [8][9]. - The gross profit margin is expected to stabilize around 11.4% for FY24E, with operating profit margins projected to improve to 3.3% [8][9]. Market Position and Future Outlook - Goertek is well-positioned to capitalize on the upcoming AR/VR product cycle, with anticipated launches from companies like Meta and Sony [2][12]. - The report emphasizes Goertek's leadership in the XR, acoustics, and gaming segments, which are expected to drive market share gains and profitability recovery in FY24 and FY25E [12][15].

21 Aug 2024 CMB 国际全球市场 | 股票研究 | 公司更新 Xpeng Inc. (XPEV US) Mona M03 可能不会改变游戏规则 保持持有。小鹏集团2024年第二季度的盈利表现基本符合我们的预测。尽管我们假设其2024 年下半年的销售量将较上年同期增长超过一倍，但我们预计下半年的亏损情况不会出现环比下 降。我们认为，小鹏汽车的车辆毛利率可能受到较低价格的Mona系列车型的影响而受限，因 为公司目前依赖这些车型来提升销量。我们认为，这种策略背后的基本理由是小鹏品牌的形象 正在减弱，尤其是在自动驾驶（AD）技术方面，竞争对手正在缩小差距。 第二季度收益基本持平。小鹏汽车2024年第二季度的收入约为我们先前预测的2%更高， 主要归功于大众（VW GR, NR）提供的研发服务。其2024年第二季度的车辆利润率为 6.4%，略高于我们的预测和2024年第一季度的5.5%，尽管季度内折扣有所增加。我们归 因于供应商的价格削减导致了这一超预期的表现。研发与销售、管理及一般费用（SG&A ）支出略高于预期，导致净亏损为人民币13亿，与预期相符。 毛利率困境。我们将FY24E的销售量预测下调10%，至 ...

2024 年 8 月 20 日 招银国际环球市场 | 睿智投资 | 行业研究 中国医药 海外 CXO/生命科学上游 2Q24 业绩剖析：生命科学上游继 续预期需求复苏 我们总结了海外主要 CXO 和生命科学上游公司的 2Q24 业绩情况，所关注的公 司涉及临床 CRO、临床前 CRO、C(D)MO以及生命科学上游。我们发现，2023 年各子板块业绩出现分化，后期阶段 CXO 业绩好于早期阶段 CXO，非生产类 CXO 的业绩好于生产类 CXO。但 1Q24 各子板块业绩差异减小，2Q24 业绩差 异继续缩窄，同时生命科学上游和 C(D)MO 公司的业绩表现较好。值得注意的 是，2Q24 仅有生命科学上游公司管理层继续预计 24 年下半年需求将复苏。 生命科学上游和 C(D)MO 公司的 2Q24 业绩表现较好。我们认为药企将更多 资源用于推进重点临床后期临床项目、新冠药物需求造成 C(D)MO 业绩基数 高、以及疫情后 C(D)MO 产能利用率相对较低导致了 2023 年子板块业绩分 化。从 1Q24 开始各子板块业绩差异持续减小，我们认为有三个原因：1） 临床 CRO 公司 2023 年业绩基数高；2）临床 ...

16 Aug 2024 JD.com (JD US) better-than-expected 2Q earnings growth | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------| | Target Price Up/Downside Current Price | | US$51.90 100.4% US$25.90 | | China Internet | | | | Saiyi HE, CFA (852) 3916 1739 hesaiyi@cmbi.com.hk | | | | Ye TAO franktao@cmbi.com.hk | | | | Wentao LU, CFA luwen ...

21 Aug 2024 CMB International Global Markets | Equity Research | Company Update Xpeng Inc. (XPEV US) Mona M03 may not be the game-changer Maintain HOLD. Xpeng's 2Q24 earnings were largely in line with our forecast. Although we assume its 2H24E sales volume to more than double HoH, we see no loss narrowing HoH in 2H24E. We believe that Xpeng's vehicle gross margin could be capped by the lower-priced Mona models, as the company now bets on these models to boost sales. We are of the view that the underlying ra ...

21 Aug 2024 CMB International Global Markets | Equity Research | Company Update Kelun-Biotech (6990 HK) Innovative bispecific ADC product licensed to MSD Kelun-Biotech recorded RMB1.38bn (+32% YoY) revenue in 1H24, including a total of US$90mn (or RMB641mn) milestone payments from MSD regarding multiple collaborated pipelines. In 1H24, Kelun-Biotech spent RMB652mn on R&D, +33% YoY, mainly driven by an uptick in clinical trials. The company is gearing up for the near-term launch of several key assets in Chin ...

Investment Rating - Initiate at BUY with a target price (TP) of HK$21.41, representing a 21.1% upside from the current price of HK$17.68 [3][4][12]. Core Insights - Rimag Group is a leading medical imaging service provider in China, holding the largest market share in terms of medical imaging centers, equipment units, and registrations by practicing radiologists [1][16]. - The medical imaging service market in China is projected to grow at a CAGR of 13.6%, reaching RMB661.5 billion by 2030, with the third-party medical imaging center market expected to grow at a CAGR of 30.7% to RMB18.6 billion by 2030 [1][7]. - Rimag's revenue increased at a CAGR of 25.3% from RMB592 million in 2021 to RMB928.9 million in 2023, with a projected CAGR of 23.3% from 2023 to 2026 [10][12][29]. Summary by Sections Investment Thesis - The third-party medical imaging center market in China has significant growth potential due to unmet demand for quality services and favorable government policies [6][7]. - Rimag is positioned to lead this market with a comprehensive suite of services and a strong operational model [7][8]. Market Overview - The medical imaging market in China faces challenges such as low equipment per capita and an imbalance in resource distribution, leading to long wait times in public hospitals [6][20]. - Rimag has established 97 imaging centers across 17 provinces, conducting approximately 20,000 examinations daily [8][16]. Business Model - Rimag operates a comprehensive medical imaging platform that includes imaging center services, imaging solution services, and Rimag Cloud services [22][24]. - The company provides operational management services to enhance the capabilities of regional and primary healthcare institutions [11][32]. Financial Performance - Rimag's attributable net profit increased from RMB0.4 million in 2022 to RMB44 million in 2023, with a net profit margin of 4.8% [10][29]. - Revenue from imaging center services accounted for 68.7% of total revenue in 2023, growing at a CAGR of 20.1% [36]. Competitive Landscape - Rimag holds 31 out of 163 third-party medical imaging center licenses in China, representing 19% of the total market [16][17]. - The company ranks second in revenue generated from imaging center services among all third-party operators in China [10][29].

Investment Rating - The report maintains a "BUY" rating for Xtep with a target price of HK$7.32, indicating a potential upside of 44.0% from the current price of HK$5.08 [4][7]. Core Views - Despite challenges in the sportswear industry, Xtep is expected to outperform in the mid to long run due to successful new product launches, strong e-commerce sales, and growth from the Saucony brand [2][7]. - The company has reiterated its FY24E guidance, projecting high single-digit to low-teens sales growth and net profit growth of 20% or above [2][7]. Financial Performance - For FY24E, revenue is projected at RMB 14,994 million, with a gross profit of RMB 6,592 million, resulting in a gross margin of 44.0% [8][11]. - The net profit attributable to shareholders is expected to reach RMB 1,264 million, with a diluted EPS of RMB 0.463 [8][11]. - In 1H24, Xtep's sales rose by 10% YoY to RMB 7.2 billion, with net profit increasing by 13% YoY to RMB 752 million [7][10]. Sales Growth and Margins - Retail sales growth for the Xtep brand is anticipated to be resilient at high single digits in 2H24E, supported by new product launches and e-commerce initiatives [2][7]. - The Saucony brand has shown remarkable performance with over 70% sales growth in 1H24, prompting an upward revision of its sales growth guidance to 50% or above [2][7]. - The report highlights improved margins due to cost control measures, economies of scale, and reduced advertising expenses [2][7]. Market Position and Strategy - Xtep is positioned as a value-for-money brand with leadership in running categories, which is expected to help it outperform the industry despite macro uncertainties [7]. - The strategic disposal of K&P has allowed the company to refocus resources on its core brand and running segments, contributing to margin expansion [2][7]. Valuation Metrics - The stock is currently trading at a P/E ratio of 10x for FY24E, which is considered attractive compared to its historical average of 15x [7][8]. - The expected dividend yield for FY24E is 14%, further enhancing the stock's appeal [7].

Investment Rating - The report maintains a "BUY" rating for Yancoal Australia with a target price revised down to HK$42 from HK$45, indicating a potential upside of 17% from the current price of HK$35.90 [2][11]. Core Insights - Yancoal's 1H24 net profit decreased by 57% year-over-year to A$420 million, primarily due to higher-than-expected unit costs and a significant decline in blended coal average selling price (ASP) [2][3]. - The company has a strong net cash position of A$1.42 billion as of the end of June 2024, which may facilitate potential M&A activities [2][3]. - Despite the challenges, Yancoal maintains its full-year guidance for production and operating cash costs, with expectations for a unit cash cost reduction in the second half of 2024 [2][3]. Financial Performance - Revenue for 1H24 was A$3.1 billion, down 21% year-over-year, with coal sales volume growth of 16.9 million tonnes being offset by lower prices [2][3]. - The unit cash operating cost in 1H24 was A$101 per tonne, a decrease of 7% year-over-year but an increase of 17% quarter-over-quarter [2][3]. - The report projects a full-year revenue of A$7.138 billion for FY24, reflecting an 8.2% decline compared to FY23 [14]. Production and Cost Guidance - Yancoal's full-year production guidance remains unchanged at 35-39 million tonnes, with operating cash costs expected to be between A$89-97 per tonne [2][3]. - The report anticipates a 7% year-over-year reduction in unit cash costs in the second half of 2024, despite the current higher cost assumptions [2][3]. Market Conditions - The blended coal ASP fell by 37% year-over-year to A$176 per tonne, contributing to the decline in revenue and profit [2][3]. - The report highlights the potential for Yancoal to benefit from product diversification and long-term growth strategies, particularly in light of its strong cash position [2][3]. Valuation Metrics - The report provides a valuation based on net present value (NPV) with key assumptions including long-term thermal and metallurgical coal prices starting in 2027 at A$130 and A$200 per tonne, respectively [11][12]. - The projected P/E ratio for FY24 is 6.6, indicating a relatively attractive valuation compared to historical performance [14].

Investment Rating - The investment rating for J&T Express has been upgraded from Hold to Buy [1][2]. Core Insights - J&T Express achieved a net profit of $31 million in the first half of 2024, a significant improvement compared to losses of $264 million and $168 million in the first and second halves of 2023, respectively [1]. - The company is on a clearer path to sustainable profitability due to ongoing cost-cutting trends in Southeast Asia and China [1]. - Revenue for the first half of 2024 grew by 22% year-on-year to $1.52 billion, driven by a 42% increase in parcel volume, although this was offset by a 14% decline in average selling price (ASP) [1][6]. - The target price has been adjusted to HK$10 from HK$12.80, reflecting a more conservative valuation approach post-industry correction [1][10]. Southeast Asia Performance - In the first half of 2024, revenue in Southeast Asia increased by 22% to $1.52 billion, with parcel volume rising by 42% to 2 billion units [1]. - The average selling price (ASP) decreased by 14% to $0.74, while market share increased by 2 percentage points to 27.4% [1][6]. - The unit gross margin only declined by 8% year-on-year to $0.14 due to a 16% reduction in annual unit costs [1]. China Performance - Revenue in China grew by 36% year-on-year to $3 billion in the first half of 2024, supported by a 37% increase in parcel volume to 8.8 billion units [1]. - The ASP remained stable at $0.34, with market share expanding by 1.1 percentage points to 11% [1][6]. - The unit cost decreased by 6% year-on-year, resulting in a gross profit of $0.02 per parcel [1]. New Markets - Revenue in new markets surged by 120% year-on-year to $292 million in the first half of 2024, driven by a 64% increase in parcel volume [1]. - However, growth is expected to moderate in the second half of 2024 due to new tariffs affecting cross-border e-commerce in Brazil [1]. Financial Projections - Revenue projections for FY24E and FY25E have been revised upwards by 12% and 7%, respectively [1][2]. - Adjusted net profit is expected to reach $186.5 million in FY24E and $495.6 million in FY25E [2]. - The company is projected to achieve a P/E ratio of 39.7x in FY24E, decreasing to 15.2x in FY25E [2]. Valuation Methodology - The target price is based on a sum-of-the-parts (SOTP) valuation approach, applying different EV/EBITDA multiples for various markets [10][11]. - Southeast Asia is assigned a target P/E of 15x, reflecting a premium due to competitive advantages and market share growth [10]. - The valuation for China has shifted to an EV/EBITDA approach, applying a target multiple of 10x, which is approximately 50% higher than local peers [10].